<p>上漲的東西也會下跌。大多數投資者都親身經歷過他們投資組合中的股票的這種情況。但是，下跌的東西能否再次上漲？在許多情況下，答案是肯定的。</p>
<p>股票價格的急劇下跌往往為長期投資者提供了絕佳的買入機會。我認為現在就存在這樣的機會。以下是兩隻被嚴重低估的股票，具有令人難以置信的上漲潛力。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. 聯合健康集團</h2>
<p><strong>聯合健康集團</strong>（UNH 1.21%）的股價已大約下跌了 50%，低於今年早些時候的高點。幾乎所有可能出錯的事情都在這家健康保險公司的股票上發生了。</p>
<p>在四月份，聯合健康集團公佈了令人失望的第一季度業績，並下調了全年的指引。不到一個月後，該公司完全暫停了全年的展望，並在前首席執行官安德魯·維蒂意外離職後任命了一位新首席執行官。</p>
<p>這並不是唯一的壞消息。《華爾街日報》在五月份報道，美國司法部正在對聯合健康集團的醫療保險賬單做法進行民事和刑事調查。該公司在七月份確認這些調查確實正在進行中。</p>
<p>但聯合健康集團在前首席執行官斯蒂芬·赫姆斯利的掌舵下，依然處於良好的管理之中。該公司當前的財務困境源於高於預期的醫療成本，特別是在其醫療保險優勢計劃中。這些問題可以通過提高保費來解決，而這正是聯合健康計劃在 2026 年要做的。</p>
<p>當然，與司法部調查相關的陰雲將在一段時間內繼續籠罩在公司頭上。之前的一次聯邦調查持續了十年。然而，在那次調查中沒有發現任何不當行為的證據。聯合健康集團似乎相信這次也會有類似的結果，公司表示 “對其做法充滿信心”。</p>
<p>億萬富翁投資者沃倫·巴菲特和大衞·泰珀，以及因《大空頭》而聞名的邁克爾·伯裏，在 2025 年第二季度購買了這家醫療巨頭的股票。他們無疑認為聯合健康集團的估值具有吸引力，其市盈率處於多年來的最低水平。</p>
<p>我懷疑巴菲特、泰珀和伯裏對聯合健康集團的前景是正確的。一旦公司的收益在明年開始再次增長，這隻被嚴重低估的股票可能會強勁反彈。</p>
<h2>2. Vertex 製藥</h2>
<p><strong>Vertex 製藥</strong>（VRTX 0.69%）在今年早些時候表現出色。然而，這種勢頭現在已經消失。該生物技術股票的股價已下跌超過 20%，低於 2025 年 3 月的峯值。</p>
<p>Vertex 的第一個警告信號出現在五月，該公司公佈的第一季度業績低於預期。收入低於分析師的預測，主要是由於公司在俄羅斯銷售的仿製版囊性纖維化（CF）藥物影響了銷售。</p>
<p>Vertex 本月早些時候宣佈了兩個管道挫折。實驗性止痛藥 VX-993 未能達到二期臨牀試驗的主要終點。該公司還透露，美國食品和藥物管理局（FDA）未看到為 Journavx 在治療外周神經病理性疼痛（PNP）提供廣泛標籤的前景。</p>
<p>儘管這一消息令人失望，但 Vertex 的積極因素仍然多於消極因素。Journavx 在美國的推出進展順利，公司正在加強其商業化努力。其最新的 CF 療法 Alyftrek 在市場上持續獲得動力。Journavx 和 Alyftrek 都應該在不久的將來成為 Vertex 的巨大暢銷藥。</p>
<p>Vertex 的管道前景仍然看好。該生物技術公司預計將在明年申請 1 型糖尿病療法 zimislecel 的全球監管批准，並申請 FDA 加速批准 povetacicept 用於治療 IgA 腎病。針對 APOL1 介導的腎病的晚期臨牀研究也在進行中。儘管 FDA 目前對 Journavx 的廣泛 PNP 標籤潑了冷水，但 Vertex 仍在推進三期研究，以爭取在糖尿病外周神經病變中獲得批准。</p>
<p>華爾街對這隻生物技術股票的 12 個月共識目標價反映出超過 21% 的上漲潛力。如果 Vertex 的已批准產品和管道候選藥物兑現其承諾，其股票在未來幾年內應該能夠大幅飆升。</p>

福泰制藥

聯合健康

<p>這篇文章討論了兩隻表現不佳但具有顯著上漲潛力的股票：聯合健康和福泰製藥。聯合健康由於令人失望的業績和持續的調查，股價下跌了 50%，但隨着新領導層的上任和提高保費的計劃，它可能會反彈。福泰製藥由於銷售疲軟和管道問題下跌超過 20%，然而它有前景良好的產品和即將獲得的監管批准，這表明在未來幾年內有恢復和增長的潛力</p>

<p>What goes up can come down. Most investors have experienced this first-hand with stocks in their portfolio. But can what comes down go back up? In many cases, the answer is a resounding yes.</p>
<div class="lb-trans"><p>上漲的東西也會下跌。大多數投資者都親身經歷過他們投資組合中的股票的這種情況。但是，下跌的東西能否再次上漲？在許多情況下，答案是肯定的。</p>
</div><p>Steep declines in share prices can often present great buying opportunities for long-term investors. I think such opportunities exist right now. Here are two beaten-down stocks with incredible upside potential.</p>
<div class="lb-trans"><p>股票價格的急劇下跌往往為長期投資者提供了絕佳的買入機會。我認為現在就存在這樣的機會。以下是兩隻被嚴重低估的股票，具有令人難以置信的上漲潛力。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjkwOTYvc3RvY2stY2hhcnQtdHJlbmRpbmctZG93bi13aXRoLW1hbi5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F829096%2Fstock-chart-trending-down-with-man.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. UnitedHealth Group</h2>
<div class="lb-trans"><h2>1. 聯合健康集團</h2>
</div><p>Shares of <strong>UnitedHealth Group</strong>(UNH 1.21%) have plunged roughly 50% below the high from earlier this year. Pretty much everything that could go wrong for the health insurance stock has gone wrong.</p>
<div class="lb-trans"><p><strong>聯合健康集團</strong>（UNH 1.21%）的股價已大約下跌了 50%，低於今年早些時候的高點。幾乎所有可能出錯的事情都在這家健康保險公司的股票上發生了。</p>
</div><p>In April, UnitedHealth Group announced disappointing first-quarter results and lowered its guidance for the full year. Less than one month later, the company suspended its full-year outlook altogether and named a new CEO after the unexpected departure of former CEO Andrew Witty.</p>
<div class="lb-trans"><p>在四月份，聯合健康集團公佈了令人失望的第一季度業績，並下調了全年的指引。不到一個月後，該公司完全暫停了全年的展望，並在前首席執行官安德魯·維蒂意外離職後任命了一位新首席執行官。</p>
</div><p>That wasn't the only bad news. <em>The Wall Street Journal</em> reported in May that the U.S. Department of Justice was conducting civil and criminal investigations into UnitedHealth Group's Medicare billing practices. The company confirmed in July that those investigations were indeed underway.</p>
<div class="lb-trans"><p>這並不是唯一的壞消息。《華爾街日報》在五月份報道，美國司法部正在對聯合健康集團的醫療保險賬單做法進行民事和刑事調查。該公司在七月份確認這些調查確實正在進行中。</p>
</div><p>But UnitedHealth Group is in good hands with former longtime CEO Stephen Hemsley back in charge. The company's current financial woes stem from higher-than-expected medical costs, particularly with its Medicare Advantage plans. Those issues can be resolved by increasing premiums, which is exactly what UnitedHealth plans to do in 2026.</p>
<div class="lb-trans"><p>但聯合健康集團在前首席執行官斯蒂芬·赫姆斯利的掌舵下，依然處於良好的管理之中。該公司當前的財務困境源於高於預期的醫療成本，特別是在其醫療保險優勢計劃中。這些問題可以通過提高保費來解決，而這正是聯合健康計劃在 2026 年要做的。</p>
</div><p>Sure, the dark cloud related to the DOJ investigations will continue to hover over the company's head for a while. A previous federal probe lasted a decade. However, no evidence of wrongdoing was found in that investigation. UnitedHealth Group seems to believe there will be a similar outcome this time around, with the company stating that it &#34;has full confidence in its practices.&#34;</p>
<div class="lb-trans"><p>當然，與司法部調查相關的陰雲將在一段時間內繼續籠罩在公司頭上。之前的一次聯邦調查持續了十年。然而，在那次調查中沒有發現任何不當行為的證據。聯合健康集團似乎相信這次也會有類似的結果，公司表示 “對其做法充滿信心”。</p>
</div><p>Billionaire investors Warren Buffett and David Tepper, along with Michael Burry of <em>The Big Short</em> fame, bought shares of the healthcare giant in the second quarter of 2025. They undoubtedly view UnitedHealth Group's valuation as attractive, with its price-to-earnings ratio at its lowest level in years.</p>
<div class="lb-trans"><p>億萬富翁投資者沃倫·巴菲特和大衞·泰珀，以及因《大空頭》而聞名的邁克爾·伯裏，在 2025 年第二季度購買了這家醫療巨頭的股票。他們無疑認為聯合健康集團的估值具有吸引力，其市盈率處於多年來的最低水平。</p>
</div><p>I suspect Buffett, Tepper, and Burry are right about UnitedHealth Group's prospects. Once the company's earnings begin to grow again next year, this beaten-down stock could rebound strongly.</p>
<div class="lb-trans"><p>我懷疑巴菲特、泰珀和伯裏對聯合健康集團的前景是正確的。一旦公司的收益在明年開始再次增長，這隻被嚴重低估的股票可能會強勁反彈。</p>
</div><h2>2. Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>2. Vertex 製藥</h2>
</div><p><strong>Vertex Pharmaceuticals</strong>(VRTX 0.69%) was on a roll earlier this year. However, that momentum is now long gone. The biotech stock has fallen more than 20% below its March 2025 peak.</p>
<div class="lb-trans"><p><strong>Vertex 製藥</strong>（VRTX 0.69%）在今年早些時候表現出色。然而，這種勢頭現在已經消失。該生物技術股票的股價已下跌超過 20%，低於 2025 年 3 月的峯值。</p>
</div><p>The first warning sign for Vertex came in May with the company's weaker-than-expected first-quarter results. Revenue was lower than analysts had predicted, primarily due to the sale of copycat versions of the company's cystic fibrosis (CF) drugs in Russia, which negatively impacted sales.</p>
<div class="lb-trans"><p>Vertex 的第一個警告信號出現在五月，該公司公佈的第一季度業績低於預期。收入低於分析師的預測，主要是由於公司在俄羅斯銷售的仿製版囊性纖維化（CF）藥物影響了銷售。</p>
</div><p>Vertex announced two pipeline setbacks earlier this month. Experimental pain drug VX-993 failed to meet the primary endpoint of a phase 2 clinical trial. The company also revealed that the U.S. Food and Drug Administration (FDA) didn't see a path forward for a broad label for Journavx in treating peripheral neuropathic pain (PNP).</p>
<div class="lb-trans"><p>Vertex 本月早些時候宣佈了兩個管道挫折。實驗性止痛藥 VX-993 未能達到二期臨牀試驗的主要終點。該公司還透露，美國食品和藥物管理局（FDA）未看到為 Journavx 在治療外周神經病理性疼痛（PNP）提供廣泛標籤的前景。</p>
</div><p>While this news was disappointing, Vertex has more positives than negatives. Journavx's U.S. launch is going so well that the company is beefing up its commercialization efforts. Its newest CF therapy, Alyftrek, continues to gain steam in the market. Both Journavx and Alyftrek should become huge blockbuster drugs for Vertex in the not-too-distant future.</p>
<div class="lb-trans"><p>儘管這一消息令人失望，但 Vertex 的積極因素仍然多於消極因素。Journavx 在美國的推出進展順利，公司正在加強其商業化努力。其最新的 CF 療法 Alyftrek 在市場上持續獲得動力。Journavx 和 Alyftrek 都應該在不久的將來成為 Vertex 的巨大暢銷藥。</p>
</div><p>Vertex's pipeline prospects still look promising, too. The biotech company expects to file for global regulatory approvals of type 1 diabetes therapy zimislecel and for FDA accelerated approval of povetacicept in treating IgA nephropathy next year. A late-stage clinical study is also in progress for inaxaplin targeting APOL1-mediated kidney disease. And while the FDA poured cold water on a broad PNP label for Journavx for now, Vertex is moving ahead with phase 3 studies to try to win approval in painful diabetic peripheral neuropathy.</p>
<div class="lb-trans"><p>Vertex 的管道前景仍然看好。該生物技術公司預計將在明年申請 1 型糖尿病療法 zimislecel 的全球監管批准，並申請 FDA 加速批准 povetacicept 用於治療 IgA 腎病。針對 APOL1 介導的腎病的晚期臨牀研究也在進行中。儘管 FDA 目前對 Journavx 的廣泛 PNP 標籤潑了冷水，但 Vertex 仍在推進三期研究，以爭取在糖尿病外周神經病變中獲得批准。</p>
</div><p>The consensus Wall Street 12-month price target for this biotech stock reflects an upside potential of over 21%. If Vertex's approved products and pipeline candidates fulfill their promise, its stock should be able to skyrocket much more than that over the next few years.</p>
<div class="lb-trans"><p>華爾街對這隻生物技術股票的 12 個月共識目標價反映出超過 21% 的上漲潛力。如果 Vertex 的已批准產品和管道候選藥物兑現其承諾，其股票在未來幾年內應該能夠大幅飆升。</p>
</div>

兩隻被嚴重低估的股票具有巨大的上漲潛力